The FDA's Urology Subcommittee of the Advisory Committee for Reproductive Health Drugs will hold an open meeting on April 10, 9 AM to 5 PM, at the Holiday Inn, 8120 Wisconsin Ave, Bethesda, Md. The committee will consider the safety and efficacy of new drug application for apomorphine hydrochloride tablets, sublingual (Uprima, TAP Holdings Inc, Deerfield, Ill) proposed for use in the treatment of erectile dysfunction. Oral presentations from the public will be scheduled from 1 PM to 2 PM.
Henney JE. Advisory Committee Meeting. JAMA. 2000;283(13):1679. doi:10.1001/jama.283.13.1679-JFD00002-3-1